AU2022270952A1 - Cd19-specific chimeric antigen receptor t-cell therapy - Google Patents

Cd19-specific chimeric antigen receptor t-cell therapy Download PDF

Info

Publication number
AU2022270952A1
AU2022270952A1 AU2022270952A AU2022270952A AU2022270952A1 AU 2022270952 A1 AU2022270952 A1 AU 2022270952A1 AU 2022270952 A AU2022270952 A AU 2022270952A AU 2022270952 A AU2022270952 A AU 2022270952A AU 2022270952 A1 AU2022270952 A1 AU 2022270952A1
Authority
AU
Australia
Prior art keywords
cells
car
cell
patients
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022270952A
Other languages
English (en)
Inventor
Ana BORONAT BARADO
María CASTELLÀ CASTELLÀ
Julio DELGADO GONZÁLEZ
Jordi ESTEVE REYNER
Manel JUAN OTERO
Mariona Pascal Capdevila
Álvaro URBANO ISPIZUA
Jordi YAGÜE RIBES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Barcelona
Hospital Clínic de Barcelona
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Original Assignee
Universitat de Barcelona
Hospital Clínic de Barcelona
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de Barcelona, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer filed Critical Universitat de Barcelona
Publication of AU2022270952A1 publication Critical patent/AU2022270952A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022270952A 2021-05-06 2022-05-06 Cd19-specific chimeric antigen receptor t-cell therapy Pending AU2022270952A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/ES2021/070316 2021-05-06
PCT/ES2021/070316 WO2022234158A1 (es) 2021-05-06 2021-05-06 Terapia de células t con receptor de antígeno quimérico específico de cd19
PCT/EP2022/062374 WO2022234134A1 (en) 2021-05-06 2022-05-06 Cd19-specific chimeric antigen receptor t-cell therapy

Publications (1)

Publication Number Publication Date
AU2022270952A1 true AU2022270952A1 (en) 2023-11-16

Family

ID=76355528

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022270952A Pending AU2022270952A1 (en) 2021-05-06 2022-05-06 Cd19-specific chimeric antigen receptor t-cell therapy

Country Status (11)

Country Link
US (1) US20240398945A1 (cg-RX-API-DMAC10.html)
EP (1) EP4334357A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024519529A (cg-RX-API-DMAC10.html)
AU (1) AU2022270952A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023023061A2 (cg-RX-API-DMAC10.html)
CA (1) CA3219214A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023003299A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023016940A2 (cg-RX-API-DMAC10.html)
JO (1) JOP20230269A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013088A (cg-RX-API-DMAC10.html)
WO (2) WO2022234158A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025040765A (ja) * 2023-09-12 2025-03-25 国立大学法人三重大学 Ｃａｒをコードする核酸分子とそれを含むベクター、ｃａｒ、ｃａｒを含む免疫細胞とその細胞を含む医薬組成物、細胞傷害活性を向上させる方法、並びにｃａｒを含む免疫細胞の製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
SI2997141T1 (sl) * 2013-05-13 2023-04-28 Cellectis CD19 specifični himerni antigenski receptor in njegova uporaba
JP7089806B2 (ja) * 2017-12-06 2022-06-23 アブクロン・インコーポレイテッド 悪性ｂ細胞を特異的に認知する抗体またはその抗原結合断片、これを含むキメラ抗原受容体及びその用途
WO2019119822A1 (en) * 2017-12-23 2019-06-27 Uwell Biopharma Inc. Pharmaceutical chimeric receptor composition and method thereof
CN108047332B (zh) * 2018-01-15 2021-08-24 阿思科力(苏州)生物科技有限公司 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用
US12331114B2 (en) * 2018-02-13 2025-06-17 Indian Institute Of Technology Bombay Humanized anti-CD19 chimeric antigen receptor, its nucleic acid sequence and its preparation
WO2020180551A1 (en) * 2019-03-05 2020-09-10 Promab Biotechnologies, Inc. Car-t cells with humanized cd19 scfv
KR20210137085A (ko) * 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도

Also Published As

Publication number Publication date
CA3219214A1 (en) 2022-11-10
MX2023013088A (es) 2024-01-24
CL2023003299A1 (es) 2024-07-05
BR112023023061A2 (pt) 2024-01-30
EP4334357A1 (en) 2024-03-13
JOP20230269A1 (ar) 2023-10-26
US20240398945A1 (en) 2024-12-05
WO2022234134A1 (en) 2022-11-10
JP2024519529A (ja) 2024-05-15
WO2022234158A1 (es) 2022-11-10
CO2023016940A2 (es) 2024-02-05

Similar Documents

Publication Publication Date Title
US20240390491A1 (en) Method and compositions for cellular immunotherapy
US20260124299A1 (en) Bite-activated car-t cells
US20240368625A1 (en) Methods and compositions for preparing genetically engineered cells
TWI840351B (zh) T細胞受體及表現其之工程化細胞
JP7433230B2 (ja) 細胞を培養するための無血清培地配合物およびその使用の方法
CN109843921B (zh) 程序性死亡1配体1(pd-l1)结合蛋白及其应用方法
JP7065782B2 (ja) Ｃｄ２０免疫療法のための組成物および方法
US11427645B2 (en) 5T4-targeting agents and methods
CN108290956B (zh) 靶向psca的嵌合抗原受体
US11890302B2 (en) Gamma delta CAR-T cells comprising Fc gamma intracellular signaling domains
KR20200108278A (ko) 조작된 ｔ 세포의 조성물을 제조하는 방법
AU2020336230A1 (en) Methods and compositions for the modification and delivery of lymphocytes
CN106554414A (zh) 抗cd19全人抗体以及靶向cd19的免疫效应细胞
AU2017355544A1 (en) Combination therapy of a T cell therapy and a BTK inhibitor
US20230125234A1 (en) Anti cd44-ctla4 bispecific antibodies
JP2020508657A (ja) Ｉｌ−１３ｒａ２を標的とする抗体及びその応用
WO2022047417A1 (en) Anti-idiotype compositions and methods of use thereof
JP2025526677A (ja) Ｂ７－ｈ３抗原結合性分子
US20240398945A1 (en) Cd19-specific chimeric antigen receptor t-cell therapy
US20240384293A1 (en) Viral vector production system
WO2024085182A1 (ja) Ｔ細胞性腫瘍の治療剤
US20250235479A1 (en) Natural killer cells expressing dual-targeting chimeric antigen receptors for cd19 and cd22, production method and uses thereof
US20220184125A1 (en) S309 chimeric antigen receptors and methods of use
HK40008962A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
HK40008962B (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof